Chenxia Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chenxia Wu has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Wei Mao
Department of Cardiology, Affiliated Zhejiang Hospital, Zhejiang University School of Medicine, Hangzhou, China
2 shared publications - Chenchen Meng
Zhejiang Chinese Medical University
1 shared publication - Conghua Ji
School of Public Health, Zhejiang Chinese Medical University, Hangzhou, China
1 shared publication - Fan Fei
Zhejiang Collaborative Innovation Center for the Brain Diseases with Integrative Medicine, Zhejiang Key Laboratory of Neuropsychopharmacology, School of Pharmaceutical Sciences, & First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, 310053, China
1 shared publication - Hongqiang Cheng
Department of Pathology and Pathophysiology, and Department of Cardiology of Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China
1 shared publication - Jiyao Xu
Department of Cardiology, Shanxi Cardiovascular Disease Hospital, 030027 Taiyuan, Shanxi, China
1 shared publication
Latest Publications
- Open Access
- 17 October 2025
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 26 (10)
Advances in Molecular Mechanisms and Precision Interventions of Cardiovascular Injuries Related to Glucose and Lipid Metabolism Disorders
This article reviews the latest research progress (2018–2025) on the molecular mechanisms linking glucose and lipid metabolism disorders (GLMDs) to cardiovascular injury, specifically atherosclerotic cardiovascular disease (ASCVD), diabetic cardiomyopathy (DbCM), heart failure (HF), and cardiac autonomic neuropathy (CAN). This review employed a targeted analysis of key publications from the PubMed, Web of Science, and EMBASE databases, as well as citation tracking, prioritizing molecular pathways and interventions for these four complications. The key mechanisms include: metabolic inflammation: the advanced glycation end products (AGEs)–receptor of AGE (RAGE) axis activates NF-κB, promotes vascular cell adhesion molecule-1 (VCAM-1)/monocyte chemoattractant protein-1 (MCP-1) overexpression, and accelerates monocyte infiltration; myocardial lipotoxicity: CD36 mediates fatty acid overload → mitochondrial damage → cyclic guanosine monophosphate-adenylate synthetase (cGAS)-STING pathway activation → myocardial apoptosis; metabolic memory: hyperglycemia continuously releases small extracellular vesicle (sEV) miR-15-16 clusters through the O-GlcNAc–CaMKIIδ–STAT1 loop, mediating remote myocardial injury; gut–heart axis disorder: Trimethylamine N-Oxide (TMAO) promotes thrombosis and endothelial injury. Precision strategies based on the above mechanisms, such as SGLT2 inhibitors to improve myocardial energy metabolism, targeting acyl-coenzyme A binding protein (ACBP)/TGR5 to alleviate lipotoxicity, and microbiota regulation, have demonstrated potential in clinical research. Future focus should include (1) GLMD heterogeneity typing; (2) tissue-targeted delivery system; (3) multi-omics–AI dynamic risk modeling.
- 17 October 2025
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 26 (10)
Open AccessAdvances in Molecular Mechanisms and Precision Interventions of Cardiovascular Injuries Related to Glucose and Lipid Metabolism Disorders
This article reviews the latest research progress (2018–2025) on the molecular mechanisms linking glucose and lipid metabolism disorders (GLMDs) to cardiovascular injury, specifically atherosclerotic cardiovascular disease (ASCVD), diabetic cardiomyopathy (DbCM), heart failure (HF), and cardiac autonomic neuropathy (CAN). This review employed a targeted analysis of key publications from the PubMed, Web of Science, and EMBASE databases, as well as citation tracking, prioritizing molecular pathways and interventions for these four complications. The key mechanisms include: metabolic inflammation: the advanced glycation end products (AGEs)–receptor of AGE (RAGE) axis activates NF-κB, promotes vascular cell adhesion molecule-1 (VCAM-1)/monocyte chemoattractant protein-1 (MCP-1) overexpression, and accelerates monocyte infiltration; myocardial lipotoxicity: CD36 mediates fatty acid overload → mitochondrial damage → cyclic guanosine monophosphate-adenylate synthetase (cGAS)-STING pathway activation → myocardial apoptosis; metabolic memory: hyperglycemia continuously releases small extracellular vesicle (sEV) miR-15-16 clusters through the O-GlcNAc–CaMKIIδ–STAT1 loop, mediating remote myocardial injury; gut–heart axis disorder: Trimethylamine N-Oxide (TMAO) promotes thrombosis and endothelial injury. Precision strategies based on the above mechanisms, such as SGLT2 inhibitors to improve myocardial energy metabolism, targeting acyl-coenzyme A binding protein (ACBP)/TGR5 to alleviate lipotoxicity, and microbiota regulation, have demonstrated potential in clinical research. Future focus should include (1) GLMD heterogeneity typing; (2) tissue-targeted delivery system; (3) multi-omics–AI dynamic risk modeling.
- Open Access
- 20 March 2025
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 26 (3) , 26740
The Critical Role of Faecalibacterium prausnitzii in Cardiovascular Diseases
Due to the continued aging of the global population, cardiovascular diseases (CVDs) remain the main cause of death worldwide, with millions of fatalities from diseases, including stroke and coronary artery disease, reported annually. Thus, novel therapeutic approaches and targets are urgently required for diagnosing and treating CVDs. Recent studies emphasize the vital part of gut microbiota in both CVD prevention and management. Among these, Faecalibacterium prausnitzii (F. prausnitzii) has emerged as a promising probiotic capable of improving intestinal health. Although preliminary investigations demonstrate that F. prausnitzii positively enhances cardiovascular health, research specifically connecting this strain to CVD outcomes remains limited. Based on current research and assessment of possible clinical applications, this paper aimed to investigate the positive effects on cardiovascular health using F. prausnitzii and its metabolites. Targeting gut flora is expected to become a mainstay in CVD treatment as research develops.
- 20 March 2025
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 26 (3) , 26740
Open AccessThe Critical Role of Faecalibacterium prausnitzii in Cardiovascular Diseases
Due to the continued aging of the global population, cardiovascular diseases (CVDs) remain the main cause of death worldwide, with millions of fatalities from diseases, including stroke and coronary artery disease, reported annually. Thus, novel therapeutic approaches and targets are urgently required for diagnosing and treating CVDs. Recent studies emphasize the vital part of gut microbiota in both CVD prevention and management. Among these, Faecalibacterium prausnitzii (F. prausnitzii) has emerged as a promising probiotic capable of improving intestinal health. Although preliminary investigations demonstrate that F. prausnitzii positively enhances cardiovascular health, research specifically connecting this strain to CVD outcomes remains limited. Based on current research and assessment of possible clinical applications, this paper aimed to investigate the positive effects on cardiovascular health using F. prausnitzii and its metabolites. Targeting gut flora is expected to become a mainstay in CVD treatment as research develops.
- 1 January 2024
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 44 (1) , 202-217
Protein Tyrosine Phosphatase SHP2 in Macrophages Acts as an Antiatherosclerotic Regulator in Mice
BACKGROUND: Macrophages have versatile roles in atherosclerosis. SHP2 (Src homology 2 containing protein tyrosine phosphatase 2) has been demonstrated to play a critical role in regulating macrophage activation. However, the mechanism of SHP2 regulation of macrophage function in an atherosclerotic microenvironment remains unknown. METHODS: APOE (apolipoprotein E) or LDLR (low-density lipoprotein receptor) null mice treated with SHP099 were fed a Western diet for 8 weeks, while Shp2 MKO :ApoE −/− or Shp2 MKO :Ldlr −/− mice and exo-AAV8-SHP2 E76K / ApoE −/− mice were fed a Western diet for 12 weeks. In vitro, levels of proinflammatory factors and phagocytic function were then studied in mouse peritoneal macrophages. RNA sequencing was used to identify PPARγ (peroxisome proliferative activated receptor γ) as the key downstream molecule. A PPARγ agonist was used to rescue the phenotypes observed in SHP2-deleted mice. RESULTS: Pharmacological inhibition and selective deletion in macrophages of SHP2 aggravated atherosclerosis in APOE and LDLR null mice with increased plaque macrophages and apoptotic cells. In vitro, SHP2 deficiency in APOE and LDLR null macrophages enhanced proinflammatory polarization and its efferocytosis was dramatically impaired. Conversely, the expression of gain-of-function mutation of SHP2 in mouse macrophages reduced atherosclerosis. The SHP2 agonist lovastatin repressesed macrophage inflammatory activation and enhanced efferocytosis. Mechanistically, RNA sequencing analysis identified PPARγ as a key downstream transcription factor. PPARγ was decreased in macrophages upon SHP2 deletion and inhibition. Importantly, PPARγ agonist decreased atherosclerosis in SHP2 knockout mice, restored efferocytotic defects, and reduced inflammatory activation in SHP2 deleted macrophages. PPARγ was decreased by the ubiquitin-mediated degradation upon SHP2 inhibition or deletion. Finally, we found that SHP2 was downregulated in atherosclerotic vessels. CONCLUSIONS: Overall, SHP2 in macrophages was found to act as an antiatherosclerotic regulator by stabilizing PPARγ in APOE/LDLR null mice.
- 1 January 2024
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 44 (1) , 202-217
Protein Tyrosine Phosphatase SHP2 in Macrophages Acts as an Antiatherosclerotic Regulator in Mice
BACKGROUND: Macrophages have versatile roles in atherosclerosis. SHP2 (Src homology 2 containing protein tyrosine phosphatase 2) has been demonstrated to play a critical role in regulating macrophage activation. However, the mechanism of SHP2 regulation of macrophage function in an atherosclerotic microenvironment remains unknown. METHODS: APOE (apolipoprotein E) or LDLR (low-density lipoprotein receptor) null mice treated with SHP099 were fed a Western diet for 8 weeks, while Shp2 MKO :ApoE −/− or Shp2 MKO :Ldlr −/− mice and exo-AAV8-SHP2 E76K / ApoE −/− mice were fed a Western diet for 12 weeks. In vitro, levels of proinflammatory factors and phagocytic function were then studied in mouse peritoneal macrophages. RNA sequencing was used to identify PPARγ (peroxisome proliferative activated receptor γ) as the key downstream molecule. A PPARγ agonist was used to rescue the phenotypes observed in SHP2-deleted mice. RESULTS: Pharmacological inhibition and selective deletion in macrophages of SHP2 aggravated atherosclerosis in APOE and LDLR null mice with increased plaque macrophages and apoptotic cells. In vitro, SHP2 deficiency in APOE and LDLR null macrophages enhanced proinflammatory polarization and its efferocytosis was dramatically impaired. Conversely, the expression of gain-of-function mutation of SHP2 in mouse macrophages reduced atherosclerosis. The SHP2 agonist lovastatin repressesed macrophage inflammatory activation and enhanced efferocytosis. Mechanistically, RNA sequencing analysis identified PPARγ as a key downstream transcription factor. PPARγ was decreased in macrophages upon SHP2 deletion and inhibition. Importantly, PPARγ agonist decreased atherosclerosis in SHP2 knockout mice, restored efferocytotic defects, and reduced inflammatory activation in SHP2 deleted macrophages. PPARγ was decreased by the ubiquitin-mediated degradation upon SHP2 inhibition or deletion. Finally, we found that SHP2 was downregulated in atherosclerotic vessels. CONCLUSIONS: Overall, SHP2 in macrophages was found to act as an antiatherosclerotic regulator by stabilizing PPARγ in APOE/LDLR null mice.